Asset marketplace 9xchange augments toolbox with PhaseV trial analytics

As the user base grows for 9xchange’s asset marketplace, the company is continuing to add tools to help drug developers identify stalled programs that can reach the right set of patients.

This month, the company announced a deal with PhaseV Trials Ltd. that will add machine learning-based clinical trials support tools to its marketplace. The partnership follows a spring 2023 agreement with BenevolentAI S.A. (Euronext:BAI), and figures to precede more deals, 9xchange Ltd. co-founder and CEO Anat Naschitz told BioCentury...